Choose TOBRADEX® ST, formulated with XanGen™, to treat ocular inflammation with risk of bacterial infection
Blepharitis, conjunctivitis, and contact lens acute red eye (CLARE) are some of the most commonly seen inflammatory ocular conditions1-3
Common presentations include:
Lid Margin Disease
Blepharitis/MGD1
- Ocular surface inflammation
- Keratitis
- Scaling, crusting, erythema of the eyelid margin
- Bacterial overgrowth on lashes (collarettes) and/or meibomian glands
Conjunctivitis
Bacterial and nonspecific2,4
- Purulent discharge
- Ocular discomfort and foreign body sensation
- Tearing
- Lid crusting
Contact Lens Acute Red Eye (CLARE)3
- Unilateral eye pain
- Photophobia
- Epiphora
- Conjunctival redness and swelling
Deliver the advantages of TOBRADEX® ST with XanGen™, an innovative suspension technology
Increased viscosity improves ocular bioavailability of drug5
The addition of xanthan gum in TOBRADEX ST5,6:
Elevates the classic combination of tobramycin and dexamethasone
Creates a unique interaction with tears that increases the viscosity of each drop
Provides longer retention on the eye and increased ocular availability of drug
10 minutes after instillation, the tobramycin concentration in tears was 8.3 times higher with TOBRADEX ST vs TobraDex® when compared in a preclinical study5,a
Consistent delivery with minimal settling 24 hours after mixing5,b
Percentage of dexamethasone per label in each drop expressed from the bottle after 24 hours5
Percentage of dexamethasone that remained suspended after 24 hours5
- Based on the results of a preclinical study that examined the concentration of tobramycin in rabbit tears following exposure to TOBRADEX ST and TobraDex.5
- Based on the results of a preclinical study that examined the suspension-settling characteristics of TOBRADEX ST compared to TobraDex.5
There is no therapeutic equivalent of TOBRADEX ST7

Preclinical Data
Increase bactericidal activity with TOBRADEX® ST
TOBRADEX ST exhibited greater and more rapid bactericidal activity than TobraDex® against tobramycin- and methicillin-resistant strains5
Based on the results of a preclinical study that examined the effectiveness in killing S aureus and S pneumoniae isolates using tobramycin concentrations measured 10 minutes following exposure to TOBRADEX ST or TobraDex in rabbit models5
TOBRADEX ST killed >99.9% of S aureus compared to 0% by TobraDex
TOBRADEX ST killed >99.9% of S pneumoniae within 5 min compared to 120 min for TobraDex
Clinical Data
Half the dexamethasone, similar ocular tissue exposure5
ng/mL
TOBRADEX® ST
vs
ng/mL
TobraDex®
In a pharmacokinetic study, the concentration of dexamethasone in the aqueous humor 2 hours after instillation was 33.7±22.8 ng/mL for patients receiving TOBRADEX ST and 30.9±16.7 ng/mL for patients receiving TobraDex.a
Provide patients rapid relief with TOBRADEX ST8
After 1 week of TOBRADEX ST dosing, patients had significant reduction in symptoms8,b
Global symptom score was determined from the following symptoms, often associated with blepharitis/blepharoconjunctivitis8
- Lid margin redness
- Ocular discharge
- Bulbar conjunctival redness
- Palpebral conjunctival redness
- Lid swelling
- Itchy eyelids
- Gritty eyes
No IOP spikes were reported during the first week of treatment. At the 2-week visit, 3 of 61 patients treated with TOBRADEX ST (4.9%) had an increase in IOP with only 1 patient having an increase of >10 mmHg8
- Multicenter, double-blind, parallel-group, single-dose study of 987 patients receiving a single dose of TOBRADEX ST or TobraDex ophthalmic suspension.5
- Randomized, multicenter, investigator-masked, active-controlled, parallel-group trial conducted in adult patients who had moderate to severe blepharitis/blepharoconjunctivitis.8

The ST makes a difference. Prescribe TOBRADEX ST.
Deliver the difference of TOBRADEX® ST
Dosing and administration6
- One drop of TOBRADEX ST should be administered to the affected eye every 4 to 6 hours
- During the initial 24 to 48 hours, dosage may be increased to one drop every 2 hours
- Frequency should be decreased gradually as clinical signs improve
- Therapy should not be discontinued prematurely


Eyevance® is committed to helping all patients have affordable access to TOBRADEX® ST
With our copay savings program, eligible patientsa could pay as little as $45
Savings >aEligible patients include those whose prescriptions are covered by commercial insurance and patients whose TOBRADEX ST prescriptions are not covered by either commercial or government insurance. See full terms and conditions at myeyesavings.com for commercial, Medicare Part D, cash pay, and government insurance patients.